Table 2.
Data of Experiment II: Ligandrol (LG).
| Groups | Non-OVX | OVX | OVX+LG 0.04 | OVX+LG 0.4 | OVX+LG 4 | ANOVA p-value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample Size | 12 | 12 | 13 | 13 | 13 | ||||||||||
| Parameters | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||||
| Weights | |||||||||||||||
| Body weight (begin of trial) [g] | 239.20 | 10.92 | 235.00 | 10.69 | 237.00 | 12.17 | 240.50 | 14.53 | 236.64 | 10.54 | 0.742 | ||||
| Body weight (begin of treatment) [g] | 273.00 | 11.90 | 332.27 | a | 17.21 | 335.40 | a | 19.81 | 333.43 | a | 25.40 | 337.57 | a | 31.44 | <0.001 |
| Body weight (end of trial) [g] | 282.47 | 14.81 | 338.67 | a | 20.53 | 342.13 | a | 27.41 | 350.39 | a | 16.33 | 355.21 | a | 19.37 | <0.001 |
| Uterus weight [g] | 0.58 | 0.11 | 0.11 | a | 0.02 | 0.11 | a | 0.02 | 0.13 | a | 0.02 | 0.43 | abcd | 0.04 | <0.001 |
| GM weight [g] | 2.03 | 0.14 | 2.29 | a | 0.14 | 2.30 | a | 0.23 | 2.45 | a | 0.20 | 2.49 | abc | 0.17 | <0.001 |
| GM weight/BW [mg/g] | 7.20 | 0.51 | 6.71 | 0.41 | 6.69 | 0.68 | 7.06 | 0.57 | 6.94 | 0.47 | 0.059 | ||||
| SM weight [g] | 0.11 | 0.02 | 0.12 | 0.02 | 0.12 | 0.03 | 0.13 | 0.02 | 0.11 | 0.03 | 0.619 | ||||
| SM weight/BW [mg/g] | 0.41 | 0.07 | 0.32 | 0.11 | 0.34 | 0.08 | 0.36 | 0.07 | 0.31 | 0.07 | 0.016 | ||||
| Muscle fibers | |||||||||||||||
| GM | |||||||||||||||
| STO+FTO | |||||||||||||||
| Area (μm2) | 2810.58 | 722.26 | 2781.12 | 432.03 | 2631.86 | 440.71 | 2888.26 | 517.74 | 2895.14 | 496.48 | 0.812 | ||||
| Diameter (μm) | 58.75 | 7.28 | 58.69 | 4.43 | 57.09 | 4.55 | 60.23 | 5.50 | 58.72 | 5.44 | 0.734 | ||||
| FTG | |||||||||||||||
| Area (μm2) | 5149.24 | 1457.48 | 5263.84 | 897.71 | 5128.98 | 975.04 | 5587.79 | 958.43 | 5950.49 | 951.88 | 0.296 | ||||
| Diameter (μm) | 79.64 | 10.95 | 81.03 | 6.97 | 79.73 | 7.71 | 83.54 | 7.01 | 85.95 | 6.70 | 0.263 | ||||
| LM | |||||||||||||||
| STO+FTO | |||||||||||||||
| Area (μm2) | 1921.24 | 381.27 | 2154.24 | 507.73 | 2240.71 | 428.29 | 2282.34 | 289.65 | 2561.80a | 589.89 | 0.018 | ||||
| Diameter (μm) | 48.77 | 4.68 | 51.37 | 6.18 | 52.48 | 5.24 | 53.16 | 3.45 | 55.98a | 6.35 | 0.024 | ||||
| FTG | |||||||||||||||
| Area (μm2) | 4021.84 | 624.27 | 4574.66 | 833.59 | 4872.13 | 981.56 | 4647.10 | 617.80 | 5426.81 | a | 1080.47 | 0.465 | |||
| Diameter (μm) | 70.98 | 5.40 | 75.50 | 7.05 | 77.79 | 7.77 | 76.24 | 5.24 | 82.06 | a | 7.77 | 0.004 | |||
| SM | |||||||||||||||
| STO | |||||||||||||||
| Area (μm2) | 3637.88 | 396.82 | 4186.24 | a | 470.72 | 3897.86 | 293.80 | 4277.79 | a | 435.12 | 4106.85 | 635.44 | 0.005 | ||
| Diameter (μm) | 66.13 | 6.24 | 72.38 | a | 4.24 | 69.87 | 2.63 | 73.15 | a | 3.66 | 71.53 | a | 5.32 | 0.002 | |
| Percentage of fibers (%) | |||||||||||||||
| STO+FTO | 46.9 | 4.6 | 43.8 | 4.4 | 43.3 | 4.1 | 43.9 | 5.2 | 45.4 | 5.3 | 0.277 | ||||
| FTG | 53.1 | 4.6 | 56.2 | 4.4 | 56.7 | 4.1 | 56.1 | 5.2 | 54.6 | 5.3 | 0.277 | ||||
| Creatine kinase | |||||||||||||||
| Serum CK level (U/l) | 5843.60 | 1520.58 | 7545.07 | 3510.27 | 5601.20 | 1834.22 | 5202.38 | 1960.71 | 5598.29 | 1929.49 | 0.061 | ||||
| Percentage of intramuscular fat (median [q1, q3]) | |||||||||||||||
| Quadriceps femoris muscle | 1.66 (1.58, 1.88) | 1.78 (1.64, 1.90) | 1.94 (1.82, 2.24) a | 0.026 | |||||||||||
Tukey test.
a
p < 0.05 vs. Non-/OVX.
b
p < 0.05 vs. OVX.
c
p < 0.05 vs. OVX+OS 0.04.
d
p < 0.05 vs. OVX+OS 0.4.
SD, Standard deviation.
The percentage of intramuscular fat was non-parametric.
q1: the first quartile, which separates the lowest 25% of the data from the highest 75%.
q3: the third quartile, which separates the highest 25% of the data from the lowest 75%.